Viral Hepatitis
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 15, 2003; 9(10): 2211-2215
Published online Oct 15, 2003. doi: 10.3748/wjg.v9.i10.2211
Expression of ORF2 partial gene of hepatitis E virus in tomatoes and immunoactivity of expression products
Ying Ma, Shun-Quan Lin, Yi Gao, Mei Li, Wen-Xin Luo, Jun Zhang, Ning-Shao Xia
Ying Ma, Yi Gao, Wen-Xin Luo, Jun Zhang, Ning-Shao Xia, The Key Laboratory of the Ministry of Education for Cell Biology and Tumor Cell Engineering, Xiamen University, Xiamen 361005, Fujian Province, China
Ying Ma, Ministry of Education Key Laboratory for Marine Environmental Science, Center for Marine Environmental Science, Xiamen University, Xiamen 361005, Fujian Province, China
Shun-Quan Lin, College of Horticulture, South China Agricultural University, Guangzhou, 510642, Guangdong Province, China
Mei Li, Xiamen Overseas Chinese Subtropical Plant Introduction Garden, Xiamen 361002, Fujian Province, China
Author contributions: All authors contributed equally to the work.
Supported by a grant from the Natural Science Foundation of Fujian Province, No. C9910004 and Xiamen Kaili Biologic Product Limited Company
Correspondence to: Ning-Shao Xia, The Key Laboratory of the Ministry of Education for Cell Biology and Tumor Cell Engineering, Xiamen University, Xiamen 361005, Fujian Province, China. nsxia@jingxian.xmu.edu.cn
Telephone: +86-592-2184110 Fax: +86-592-2184110
Received: March 12, 2003
Revised: July 8, 2003
Accepted: July 15, 2003
Published online: October 15, 2003

Abstract

AIM: To transfer hepatitis E virus (HEV) ORF2 partial gene to tomato plants, to investigate its expression in transformants and the immunoactivity of expression products, and to explore the feasibility of developing a new type of plant-derived HEV oral vaccine.

METHODS: Plant binary expression vector p1301E2, carrying a fragment of HEV open reading frame-2 (named HEV-E2), was constructed by linking the fragment to a constitutive CaMV35s promoter and nos terminator, then directly introduced into Agrobacterium tumefaciens EHA105. With leaf-disc method, tomato plants medicated by EHA105 were transformed and hygromycin-resistant plantlets were obtained in selective medium containing hygromycin. The presence and integration of foreign DNA in transgenic tomato genome were confirmed by Gus gene expression, PCR amplification and Southern dot blotting. The immunoactivity of recombinant protein extracted from transformed plants was examined by enzyme-linked immunosorbant assay (ELISA) using a monoclonal antibody specifically against HEV. ELISA was also used to estimate the recombinant protein content in leaves and fruits of the transformants.

RESULTS: Seven positive lines of HEV-E2-transgenic tomato plants confirmed by PCR and Southern blotting were obtained and the immunoactivity of recombinant protein could be detected in extracts of transformants. The expression levels of recombinant protein were 61.22 ng/g fresh weight in fruits and 6.37-47.9 ng/g fresh weight in leaves of the transformants.

CONCLUSION: HEV-E2 gene was correctly expressed in transgenic tomatoes and the recombinant antigen derived from them has normal immunoactivity. Transgenic tomatoes may hold a good promise for producing a new type of low-cost oral vaccine for hepatitis E virus.




INTRODUCTION

Research on using plants for expression and delivery of oral vaccine has attracted much academic attention and has become a hot spot of study since 1990 when Curtiss et al first reported the expression of Streptococcus mutans surface protein antigen A (SpaA) in tobacco, and great progress has been made since then[1]. So far, more than 10 viral epitopes and subunits of bacterial toxins have been successfully expressed in plants, mainly including hepatitis B surface antigen (HBsAg)[2-9], E.coli heat-labile enterotoxin B subunit (LT-B)[10-15], cholera toxin B subunit (CT-B)[16], Norwalk virus capsid protein (NVCP)[17,18], rabies virus glycoprotein[19], etc. The involved plant receptors are mostly mode species: tobacco, potato, etc., some fruits and vegetables that can be consumed raw, tomato, banana, lettuce and lupine have also been attempted. Significant breakthrough has been achieved in increasing the expression of vaccine components in plants. At present, the plant-derived oral vaccines from potato for HBsAg and LT-B are undergoing clinical trials[13,14], but there has been no report about plant-derived oral vaccine for hepatitis E virus (HEV).

HEV is the major cause of acute, enteric non-A, non-B (NANB) hepatitis in the world, and large outbreaks occur primarily in underdeveloped countries. China is one of the high epidemic areas. The highest infection rate is in young adults (15-40 years). Although only 1% to 3% of non-pregnant patients with HEV infection progress to fatal fulminant hepatitis, the mortality can be as high as 20% in pregnant patients[20]. There is neither effective antiviral drugs nor vaccine against HEV available for commercial use at present. Since HEV pathogen is difficult to culture, it is not easy to develop the live attenuated strains for vaccine. A promising approach is to develop recombinant subunit vaccines. Compared with gene engineering vaccine for hepatitis B, the study of hepatitis E recombinant vaccine was only a recent endeavor, but some progress has been made.

ORF2-encoded protein of HEV is the most promising subunit vaccine candidate because it possesses good antigenicity. So far, HEV ORF2 gene or its fragments have been expressed in prokaryote cells[21-24], insect cells[25], animal cells[26], and Pichia pastoris[27], etc., and the expression products possessed immunogenicity. HEV vaccine is about to undergo clinical trials[28].

Since hepatitis E occurs primarily in developing countries and impoverished regions with poor environmental sanitation, where administration of various medicinal vaccines may be hampered by the relatively high cost. Plant-derived hepatitis E vaccine is a promising approach that may solve the problem because of its low cost for delivery and administration, and its safety for humans.

Tomato is a nutrition-rich fruit that can be consumed raw and easily transformed, so it is an ideal plant carrier for oral vaccine. In this paper we reported that a plant expression vector of HEV antigen gene was constructed and transformed into tomato plants with Agrobacterium tumefaciens, and its expression in plants and immunoactivity of the expression product were examined. This study would lay the foundation for further research on the development of a new type of plant-derived hepatitis E oral vaccine or other oral vaccines, and promote their practical application.

MATERIALS AND METHODS
Plant material

Tomato (Lycopersium esculentum CV. “XiuNu”) seeds were purchased from Xiamen Nong-You Seed Co., Ltd.

Reagents, bacteria and plasmids

Restriction endonucleases and T4 DNA ligase were obtained from Promega Co. Hygromycin and X-gluc staining solution from Calbiochem-novabiochem Co. and Amres Co., respectively. Double antibody sandwich-ELISA kit was provided by Beijing Wantai Biological Pharmaceutical Co. Agrobacterium tumefaciens strain EHA105 was kindly presented by Professor Zhang Qi-fa, Huazhong Agricultural University. Plasmid pBPFΩ7 containing CaMV35s promoter and nos terminator, and plant binary plasmid pCAMBIA1301 containing hygromycin-resistant gene, kanamycin-resistant gene and Gus gene, were constructed and preserved in our laboratory.

Construction of plant binary expression vector

An 810 bp DNA fragment (named E2) of HEV ORF2 region, located between amino acid residue 394 and 604[23], was obtained by a PCR-based assembly from the patient’s serum and inserted into pBPFΩ7 between CaMV35S promoter and nos terminator at BamHI/EcoRI site to form pBE2. The fragment containing “P35S + Ω + E2 + Tnos” was isolated by gel extraction from plasmid pBE2 after PstI restrictive digestion and then subcloned into plasmid pCAMBIA1301 that had been digested by the same restriction endonuclease to yield the reconstructed plant binary expression plasmid p1301E2 (Figure 1). Confirmed by restriction digestion, p1301E2 was directly introduced into Agrobacterium tumefaciens strain EHA105 by freeze-thaw method.

Figure 1
Figure 1 Structure of plasmid p1301E2.
Plant transformation and regeneration

Tomato was transformed through leaf discs mediated by Agrobacterium tumefaciens EHA105 with p1301E2. Shoots were generated from transformed callus after 3-4 weeks selected on medium containing 20 mg of hygromycin (Hyg) and 300 mg of cefotaxime per liter. The rooting was obtained in medium containing 20 mg of Hyg per liter, and the plantlets was transplanted to soil, and watered with 1/2 MS medium.

Analysis of Gus gene expression

Both transformed and untransformed tissues were cut from tomato plants, immerged into Gus reaction buffer (X-gluc staining solution) for 12 to 24 hours at 37 °C, then bleached with absolute alcohol, observed and photographed under dissecting microscope.

Analysis of HEV-E2 gene integration

PCR amplification Genomic DNAs extracted from leaves of tomato plants by CTAB[29] were used as PCR templates. The forward primer HEFP and reverse primer HERP were: 5’-GGATCCATATGCAGCTGTTCTACTCTCGTC-3’ and 5’-CTCGAGAAATAAACTATAACTCCCGA-3’, respectively (synthesized by BioAsia Co., Shanghai). PCR reaction was performed using 50 ng of template DNA, 0.5 μM of each primer in a total volume of 30 μL. Cycling parameters were at 94 °C for 10 min, followed by 35 cycles at 94 °C for 50 s, at 57 °C for 50 s, and at 72 °C for 50 s, and a final extension at 72 °C for 7 min.

Southern dot blotting It was performed as reported previously[29].

Analysis of HEV-E2 gene expression

ELISA Total soluble proteins were extracted from leaf and fruit tissues as described[29], and HEV-E2 recombinant protein was detected by HEV enzyme-linked immunosorbant assay (ELISA) kit, the protocol and positive determination were performed according to the instructions supplied with the kit. The expression levels of HEV-E2 in transformants were quantified by ELISA. The extract of transformant was diluted several fold until it could reach the same OD value (measurement wavelength: 450 nm) as the standard HEV-E2 protein (1 ng/mg), then HEV-E2 expression levels in transformants could be calculated according to the sampling quantity, and diluting times.

RESULTS
Regeneration of transgenic tomato plants

The plasmids for expression of HEV-E2 in plants allowed morphogenesis of transformants on selective medium containing hygromycin. Through about 1 month of selection, 7 independent Hyg-resistant plantlets were obtained. These transformants bore fruits and the seeds were collected. The flowers and fruits of the transformants resembled those of wild-type tomato plants and the seeds were plump. Each fruit produced approximately 70 seeds. This demonstrated that the introduction of foreign gene into tomato plants did not influence the normal growth and development of the transformants (Figure 2).

Figure 2
Figure 2 Transgenic plants in greenhouse. A: Flowers of transformants, B: Fruits of transformants.
Gus expression in transgenic plants

Untransformed tissues appeared colourless when stained with Gus reaction solution and bleached with absolute alcohol, whereas transformed tissues presented blue spots even after bleached with absolute alcohol, the spots were generally large in size, with a deep blue color (Figure 3). The results indicated that Gus gene was stably integrated into the genomic DNA of transformed tomatoes.

Figure 3
Figure 3 Analysis of Gus gene expression. A: Leaf of untransformed tomato plant, B: Leaf of transformed tomato plant, C: Flesh of untransformed tomato, D: Flesh of trans-formed tomato.
PCR amplification

The expected 810 bp fragments were amplified from 7 transformed lines of tomatoes, the length of the fragments was identical with that amplified from p1301E2 (positive control), whereas there was no PCR product in wild-type tomato plants (negative control). The results primarily verified that the target gene was integrated into the genomic DNA of transformed tomatoes (Figure 4A).

Figure 4
Figure 4 Analysis of HEV-E2 gene integration. A: PCR amplifi-cation of genomic DNA of tomato plants, B: Southern dot blot-ting of genomic DNA of tomato plants. A1: DL-2000 marker, A2: Positive control (p1301E2), A3: Total DNA of wild-type con-trol plant, A4-A10: Total DNA of independent transformants. B1: Total DNA of wild-type control plant, B2: Positive control (p1301E2), B3-B8: Total DNA of independent transformants.
Southern dot blotting

To further verify the integration of foreign gene into tomato plants, the total genomic DNA of transformed tomatoes was hybridized by a DIG-labeled probe (encompassing the coding region of HEV-E2 gene) generated by PCR amplification from p1301E2 with HEFP and HERP primers, and all the transformants gave the same hybridization spots as the positive control (p1301E2) did, whereas the untransformed plant showed no detectable hybridization signal (Figure 4B, Figure 5). Thus the results further confirmed that the target gene was integrated into the tomato plants.

Figure 5
Figure 5 HEV-E2 expression levels in transgenic tomato plants. 1: Leaves of wild-type control plant, 2-8: Leaves of seven inde-pendent transformants, 9: The mixed flesh tissue of 3 indepen-dent transformant fruits.
Expression of HEV-E2 gene in transgenic tomato plants

The leaf extracts of 7 lines of transformants and the mixed fruit tissue extracts from 3 transformants were tested by ELISA for the presence of HEV-E2 expression products, and foreign protein could be detected in all of the examined samples. The reaction was specific because wild-type tomato showed no detectable expression products. The result demonstrated that HEV-E2 gene was expressed in transformed tissue. The expression level of HEV-E2 protein was lower as compared to HBsAg in transgenic tomatoes[8], the maximal expression level was only 47.9 ng/g fresh weight in leaves. The expression levels were different between different transformants and between different organs of the same plant, which indicated that the inserting site of foreign DNA into the plant genome was random. The expression in fruits (61.22 ng/g fresh weight) was higher than that in leaves, which was similar to that of HBsAg in transgenic tomatoes[8]. The higher expression of target protein in edible tissue mightbe helpful for producing oral vaccine.

DISCUSSION

The most striking advantage of using tomato as oral vaccine vector is that the plant-derived vaccine is cheap and tomato is a freshly-eaten fruit, which allows the target population to acquire immunity at the same time when they enjoy the delicious fruits. But accumulation of protein in tomato itself is low, the expression levels of foreign protein in it are much lower. This will make it difficult when administering the plant-derived vaccine. However, the expression of foreign protein in plants might be increased by several modifications, including the use of stronger promoters, the use of plant-derived leader sequences and signal peptide, and targeting the protein for retention in edible tissue and so on[1]. For example, Mason et al[2] increased the level of HBsAg 11 fold in transgenic tobacco by linking CaMV35S promoter to the tobacco etch virus (TEV) 5’ leader sequence (acts as a translational enhancer). In 1998, Mason et al[12] increased the expression of LT-B in transgenic potatoes 3-14 times by designing and constructing a plant-optimized synthetic gene encoding LT-B. Tackaberry et al[30] reported the synthesis of recombinant glycoprotein B which expressed specifically in tobacco seeds, with expression level reaching 70-146 ng/mg extracted protein. Lauterslager et al[11] made a synthetic gene coding for LT-B and optimized it for expression specifically in potato tubers and accumulation in endoplasmic reticulum, which resulted in a high expression level about 13 µg/g fresh weight of LT-B in potato tubers. Besides, by using chloroplast expression system, Cosa et al[31] introduced foreign genes into the chromoplast genome, which enabled the foreign protein to accumulate at 46% of the total soluble protein in leaves of transgenic plants. All these studies provided us successful experiences in improving expression level of HEV-E2 in transgenic tomatoes. In our study, we only inserted an enhancer Ω in the promoter, there were many reconstruction possibilities to achieve high expression. Currently we are engaged in researches on increasing expression level of foreign proteins, and the animal trials of oral immunization of mice with transgenic tomatoes expressing HEV-E2 are also in progress.

We have successfully introduced HEV-E2 gene into tomatoes and identified the expression protein. The expression product possessed HEV specific antigenicity in transgenic plants. Previous studies also demonstrated that plant-derived vaccines were safe and functional. It is cheap to produce and store, easy to deliver and administer, it has many advantages over other vaccines. Although this technology is not likely to produce great commercial value in the short term, the present advance in plant genetic engineering demonstrates that there is a tremendous potential to develop various low-cost recombinant vaccines by using plants.

Footnotes

Edited by Zhu LH

References
1.  Ma Y, Zhang J, Lin SQ, Xia NS. Genetic Engineering vaccines produced by transgenic plants. Xiamen Daxue Xuebao. 2001;40:S71-77.  [PubMed]  [DOI]
2.  Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA. 1992;89:11745-11749.  [PubMed]  [DOI]
3.  Thanavala Y, Yang YF, Lyons P, Mason HS, Arntzen C. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci USA. 1995;92:3358-3361.  [PubMed]  [DOI]
4.  Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci USA. 2001;98:11539-11544.  [PubMed]  [DOI]
5.  Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki AB. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 1999;13:1796-1799.  [PubMed]  [DOI]
6.  Liu DH. Plant as a system for production of pharmaceutical proteins. Shengwu Jishu Tongbao. 1999;4:1-5.  [PubMed]  [DOI]
7.  Zhao CH, Wang R, Zhao CS, Wang GL, Tian B. Expression of human hepatitis B virus surface antigen gene with and without preS in transgenic tomato. Nongye Shengwu Jishu Xuebao. 2000;8:85-88.  [PubMed]  [DOI]
8.  Ma Y, Lin SQ, Gao Y, Zhang J, Lu LX, Xia NS. Transformation of HBsAg (hepatitis B virus surface antigen) into tomato plants. Fujian Nonglin Daxue Xuebao. 2002;31:223-227.  [PubMed]  [DOI]
9.  Gao Y, Ma Y, Li M, Cheng T, Li SW, Zhang J, Xia NS. Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg. World J Gastroenterol. 2003;9:996-1002.  [PubMed]  [DOI]
10.  Haq TA, Mason HS, Clements JD, Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science. 1995;268:714-716.  [PubMed]  [DOI]
11.  Lauterslager TG, Florack DE, van der Wal TJ, Molthoff JW, Langeveld JP, Bosch D, Boersma WJ, Hilgers LA. Oral immunisation of naive and primed animals with transgenic potato tubers expressing LT-B. Vaccine. 2001;19:2749-2755.  [PubMed]  [DOI]
12.  Mason HS, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine. 1998;16:1336-1343.  [PubMed]  [DOI]
13.  Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med. 1998;4:607-609.  [PubMed]  [DOI]
14.  Tacket CO, Reid RH, Boedeker EC, Losonsky G, Nataro JP, Bhagat H, Edelman R. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine. 1994;12:1270-1274.  [PubMed]  [DOI]
15.  Streatfield SJ, Jilka JM, Hood EE, Turner DD, Bailey MR, Mayor JM, Woodard SL, Beifuss KK, Horn ME, Delaney DE. Plant-based vaccines: unique advantages. Vaccine. 2001;19:2742-2748.  [PubMed]  [DOI]
16.  Arakawa T, Chong DK, Langridge WH. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat Biotechnol. 1998;16:292-297.  [PubMed]  [DOI]
17.  Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA. 1996;93:5335-5340.  [PubMed]  [DOI]
18.  Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis. 2000;182:302-305.  [PubMed]  [DOI]
19.  McGarvey PB, Hammond J, Dienelt MM, Hooper DC, Fu ZF, Dietzschold B, Koprowski H, Michaels FH. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology (N Y). 1995;13:1484-1487.  [PubMed]  [DOI]
20.  Skidmore S. Overview of Hepatitis E Virus. Curr Infect Dis Rep. 2002;4:118-123.  [PubMed]  [DOI]
21.  Zhang M, Zhao H, Jiang Y. [Expression of hepatitis E virus structural gene in E. coli]. Zhonghua Shiyan He Linchuang Bingduxue Zazhi. 1999;13:130-132.  [PubMed]  [DOI]
22.  Bi S, Lu J, Jiang L, Huang G, Pan H, Jiang Y, Zhang M, Shen X. Preliminary evidence that a hepatitis E virus (HEV) ORF2 re-combinant protein protects cynomolgus macaques against chal-lenge with wild-type HEV. Zhonghua Shiyan He Linchuang Bingduxue Zazhi. 2002;16:31-32.  [PubMed]  [DOI]
23.  Li SW, Zhang J, He ZQ, Ge SX, Gu Y, Lin J, Liu RS, Xia NS. [The study of aggregate of the ORF2 peptide of hepatitis E virus expressed in Escherichia coli]. Shengwu Gongcheng Xuebao. 2002;18:463-467.  [PubMed]  [DOI]
24.  Zhang M, Yi Y, Zhan M, Liu C, Bi S. [Expression of thermal stable, soluble hepatitis E virus recombinant antigen]. Zhonghua Shiyan He Linchuang Bingduxue Zazhi. 2002;16:20-22.  [PubMed]  [DOI]
25.  Zhang M, Emerson SU, Nguyen H, Engle R, Govindarajan S, Blackwelder WC, Gerin J, Purcell RH. Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques. Vaccine. 2002;20:3285-3291.  [PubMed]  [DOI]
26.  Jameel S, Zafrullah M, Ozdener MH, Panda SK. Expression in animal cells and characterization of the hepatitis E virus structural proteins. J Virol. 1996;70:207-216.  [PubMed]  [DOI]
27.  Tong Y, Zhan M, Lu J, Bai Y, Bi S. Immunogenicity of recombi-nant HEV ORF2 protein expressed in pichia pastoris. Zhonghua Shiyan He Linchuang Bingduxue Zazhi. 2002;16:23-26.  [PubMed]  [DOI]
28.  Ling X. The development of hepatitis E vaccine in China. Zhonghua Yixue Zazhi. 2001;81:120.  [PubMed]  [DOI]
29.  Wang GL, Fang HJ. Principle and technology of plant genetic engineering, 1st ed, Beijing: Science Press. 1998;.  [PubMed]  [DOI]
30.  Tackaberry ES, Dudani AK, Prior F, Tocchi M, Sardana R, Altosaar I, Ganz PR. Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological re-activity of human cytomegalovirus glycoprotein B (UL55) in seeds of transgenic tobacco. Vaccine. 1999;17:3020-3029.  [PubMed]  [DOI]
31.  De Cosa B, Moar W, Lee SB, Miller M, Daniell H. Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat Biotechnol. 2001;19:71-74.  [PubMed]  [DOI]